SCHEMBL5832803

SCHEMBL5832803

COc1c(I)ccc(C(=O)O)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.47
MAPT P10636 1/20 0.47
TPMT P51580 1/20 0.42
ALDH1A1 P00352 5/20 0.40
HSD17B10 Q99714 3/20 0.40
POLB P06746 1/20 0.40
TSHR P16473 1/20 0.39
KDM4E B2RXH2 3/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
APP P05067 1/20 0.37
CYP1A2 P05177 1/20 0.37
HPGD P15428 3/20 0.36
HTT P42858 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MYC P01106 1/20 0.36
AKR1C3 P42330 2/20 0.36
AKR1C2 P52895 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2553039 0.85 TDP1 (0.47) TDP1MAPTTPMTALDH1A1HSD17B10
SCHEMBL26730159 0.81 TDP1 (0.66) TDP1MAPTTPMTALDH1A1HSD17B10
SCHEMBL11218412 0.81 TDP1 (0.50) TDP1MAPTALDH1A1HSD17B10POLB
SCHEMBL27685713 0.80 TDP1 (0.46) TDP1MAPTTPMTALDH1A1HSD17B10
SCHEMBL2425023 0.79 MAPT (0.68) TDP1MAPTTPMTALDH1A1HSD17B10
SCHEMBL30466426 0.79 MAPT (0.68) TDP1MAPTTPMTALDH1A1HSD17B10
SCHEMBL2059405 0.79 TDP1 (0.53) TDP1MAPTTPMTALDH1A1HSD17B10
SCHEMBL28007255 0.78 CYP1A2 (0.44) TDP1ALDH1A1HSD17B10TSHRKDM4E
SCHEMBL2429962 0.78 TDP1 (0.47) TDP1MAPTALDH1A1HSD17B10POLB
SCHEMBL979782 0.78 HSD17B10 (0.51) TDP1MAPTTPMTALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087601-B2 Metabotropic glutamate receptor-5 modulators MERCK & CO., INC. (US) 2006-08-08 US disclosed
EP-1453815-A4 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO INC (US) 2005-04-06 EP disclosed
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators MERCK SHARP & DOHME CORP. 2005-03-24 US disclosed
EP-1453815-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS Merck & Co., Inc. (US) 2004-09-08 EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO disclosed
WO-2003048137-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO., INC. (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators GRM5, GRIK5, GRM1 TDP1 4569/4885MAPT 2892/4885TPMT 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.